Author

Sung Young Lee 1

1 Celltr

DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF CT-P13 (INFLIXIMAB): MAINTENANCE SUBCUTANEOUS ADMINISTRATION MAY ELICIT LOWER IMMUNOGENICITY COMPARED TO INTRAVENOUS TREATMENT

Shomron Ben-Horin, Walter Reinisch, Byong Duk Ye, Rene Westhovens, Dae Hyun Yoo, Sang Joon Lee, Sung Young Lee, Mi Rim Kim, Stefan Schreiber

EARLY EFFECTIVENESS IN INFLAMMATORY BOWEL DISEASE PATIENTS WHO WERE TREATED WITH CT-P13

Sang Hyoung Park, Ji Hyun Lee, Suck Ho Lee, Hyeok Jin Kwon, Dong Il Park, Hyung kil Kim, Jae Hee Cheon, Jong Pil Im, You Sun Kim, Sang Joon Lee, Sung Young Lee, Sun Hee Lee, Ti Na Pyo, Young Ho Kim

EARLY INFLIXIMAB TROUGH LEVELS PREDICT LATE EFFICACY OF INFLIXIMAB IN A RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE CROHN'S DISEASE COMPARING CT-P13 AND INNOVATOR INFLIXIMAB

Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Changsoo Eun, Sung Young Lee, Seul Gi Lee, Joon Ho Lee, Houng Kim, Pamela Selema, Raymond Cheung, Stefan Schreiber

PHASE III RANDOMIZED CONTROLLED TRIAL TO COMPARE BIOSIMILAR INFLIXIMAB (CT-P13) WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH ACTIVE CROHN’S DISEASE: 1-YEAR MAINTENANCE AND SWITCHING RESULTS

Young-Ho Kim, Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Ágnes Szabone Salamon, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano, Radu-Bogdan Mateescu, Kang Moon Lee, Chang Soo Eun, Sang Joon Lee, Sung Young Lee, Alex Kudrin

Item 1 - 4 / 4
1